Everest Organics Limited is an **ISO 9001:2015** and **WHO GMP** certified pharmaceutical company headquartered in India. It specializes in the development and manufacture of **Active Pharmaceutical Ingredients (APIs)** and **Intermediates**. Operating from a primary manufacturing base in **Telangana**, the company serves a global clientele across **48 countries**, positioning itself as a key player in the gastrointestinal and cardiovascular therapeutic segments. --- ### **Core Manufacturing Capabilities & Regulatory Status** The company operates a sophisticated manufacturing ecosystem designed to handle complex chemical synthesis and high-volume production. * **Primary Facility:** Located at **Aroor Village, Sangareddy (Medak) District, Telangana**. * **Operational Efficiency:** The facility currently maintains a high capacity utilization rate of **80-90%**. * **USFDA Compliance:** The site underwent a **USFDA CGMP** inspection in **May 2024**, resulting in **zero 483 observations**. This allows the company to maintain **Drug Master Files (DMFs)** to support **Abbreviated New Drug Applications (ANDAs)** for the regulated U.S. market. * **Global Standards:** The company adheres to **WHO-GMP** and **Current Good Manufacturing Practices (CGMP)**, facilitating its expansion into highly regulated international territories. --- ### **Product Portfolio & Therapeutic Specialization** Everest Organics focuses on high-demand therapeutic areas, with a dominant position in the **Proton Pump Inhibitor (PPI)** market. * **Gastrointestinal Segment:** * **Rabeprazole Sodium API:** A flagship product for **GERD** and peptic ulcers. In **February 2025**, it received **Korea Drug Master File (KDMF)** approval. * **Vonoprazan:** A novel potassium-competitive acid blocker recently added to the portfolio. * **Other PPIs:** Includes Omeprazole, Esomeprazole, and Pantoprazole (all with filed **USDMFs**). * **Cardiovascular & Anticoagulants:** * **Edoxaban:** Recently launched to diversify into cardiovascular care. * **Rivaroxaban:** Currently awaiting DMF approval. * **Specialty & Emerging Drugs:** * **Bilastine** and **Posaconazole** (filed in Europe). * **Pemetrexed Intermediates:** Recently commercialized. * **Oseltamivir** and **Fenofibrate:** In the regulatory pipeline. --- ### **Strategic Growth: Capacity Expansion & Vertical Integration** The company is transitioning from a traditional API manufacturer to an integrated pharmaceutical services provider. * **Infrastructure Expansion:** A new **25,000 sq. ft.** production block is under development at **Sadashivpet, Telangana**, with a capacity of **100 tonnes per annum (TPA)** (or **60,000 Kgs**). * **Service Diversification:** Actively venturing into **Contract Development and Manufacturing Operations (CDMO)** and **Contract Manufacturing Operations (CMO)** to leverage its chemistry expertise. * **Value Chain Integration:** * **Forward Integration:** Establishing a **Pellets R&D Centre** to develop value-added dosage forms. * **Backward Integration:** Pursuing internal production of key intermediates to reduce reliance on external suppliers. * **Market Expansion Targets:** Aims to grow its client base from **85** to **120** and its geographic reach from **48** to **60+ countries** by **2027-28**. --- ### **Financial Performance & Capital Structure** Everest Organics has recently strengthened its balance sheet through strategic fundraising to support its aggressive capex plans. **Recent Quarterly Turnover (₹ Cr):** | Period | Total Turnover | Domestic | Export | | :--- | :--- | :--- | :--- | | **Q3 FY 2024-25** | **42.05** | **34.30** | **7.75** | | **Q2 FY 2024-25** | **44.05** | **36.67** | **7.38** | | **Q1 FY 2024-25** | **32.45** | **29.47** | **2.98** | **January 2025 Preferential Issue:** The company raised **₹30.00 Crore** to fund the new production block (**₹10 Cr**) and working capital (**₹20 Cr**). * **Equity Shares:** **1,710,526** shares issued at **₹152** (Total **₹26 Cr**). * **Convertible Warrants:** **263,157** warrants issued to Promoters at **₹152** (Total **₹4 Cr**). * **Paid-up Capital:** Increased from **₹8.00 Cr** to **₹9.71 Cr**. **Debt Profile (FY 2024):** * **Total Outstanding (HDFC & Canara):** Approximately **₹57.29 Cr**. * **Credit Rating (ICRA):** Long-term **[ICRA] B+ (Stable)**; Short-term **[ICRA] A4**. --- ### **Research, Development & Supply Chain** Innovation is a core pillar, with R&D activities focused on process optimization and new molecule development. * **R&D Investment:** Development costs are capitalized as **'Intangible Asset - Product under Development'**. Recent audits noted **₹1.24 crore** to **₹2.1 crore** in such capitalizations. * **Gestation Period:** New products typically require **3 to 5 years** from development to commercialization. * **Sourcing Strategy:** The company is shifting toward domestic self-reliance. In **FY 2023-24**, **84.50%** of raw materials were sourced indigenously, up from **82.62%** the previous year. * **MSE Engagement:** Significant reliance on Micro and Small Enterprises, with outstanding balances of **₹2,199.30 Lakhs** as of FY 2024. --- ### **Operational Risks & Regulatory Challenges** Investors should note several critical risks and audit qualifications that impact the company's operational stability. * **Environmental Compliance:** The company is currently operating at production levels exceeding **TSPCB** limits set in **2017**. It lacks the necessary **Consent for Establishment (CFE)** and **Consent for Operation (CFO)** for this additional capacity, posing a risk of a **Closure Order**. * **Audit Qualifications:** * **Revenue Recognition:** Discrepancies in "transfer of control" timing led to an understatement of Q1 FY25 turnover by **₹12.92 Cr**. * **Unprovided Liabilities:** Failure to provide for **₹1.43 Cr** in supplier interest and understating gratuity liabilities by **₹84.86 Lakhs**. * **Legal Contingencies:** * **NCLT:** A Section 9 insolvency application was filed by a supplier in **May 2024** regarding a **₹2.4 Cr** default (partially repaid). * **PBERF:** Potential liability of **0.5% of annual turnover** for the Environment Relief Fund, retroactive to **FY 2016-17**. * **Internal Controls:** Auditors have identified weaknesses in **fixed asset tagging**, **vendor reconciliation**, and **manual attendance systems**. * **Market Pressures:** Intense competition from low-cost producers in **China** and **Israel**, alongside wage inflation and the expansion of the **Drugs Price Control Order (DPCO)** in India.